已关闭
  • 文献求助详情
标题
Combination BRAF/MEK inhibitors for melanoma with active brain metastases: A real-world multi-center experience
网址
求助人暂未提供
DOI
暂未提供,该求助的时间将会延长,查看原因?
其它 Melanoma metastatic to the brain remains a treatment challenge. BRAF and MEK kinase inhibitors (BRAF/MEK-I) can elicit rapid responses in BRAF-mutant melanomas, but their clinical develop-ment was largely limited to patients without active/symptomatic brain metastases. We conducted a multi-center retrospective study in real-life patients with melanoma and active brain metastases treated with combination BRAF/MEK-I. Sixty-five patients were included (38 men and 27 women, median age 49). Prior to initiation of BRAF/MEK-I, 44 patients had received another systemic therapy (immunotherapy in 23 cases), 18 had brain surgery, and 40 had brain radiation. LDH was normal in 26 patients, 1-2x elevated in 20, and >2x elevated in 11. For treatment, 53 patients received dabrafenib/trametinib, 10 received vemurafenib/cobimetinib, 1 received encorafenib/binimetinib, and 1 received vemurafenib/trametinib. There were no new treatment-related safety signals in our cohort. Seventeen patients continued on therapy through the cut-off date. After initiation of therapy, steroid dose could be decreased in 20 of 33 patients (10 tapered off entirely), anticon-vulsants were stopped in 4 of 21, and narcotics were stopped in 4 of 12. Median progression-free survival (PFS) from the start of BRAF/MEK-I was 5.3 months (95% CI 3.6-6.1), and median overall survival (OS) was 9.5 months (95% CI: 7.7-13.5). Twenty patients were surviving at the cut-off date. Univariate analysis of age, sex, ulceration status, thickness, stage, location, or LDH did not reveal significant predictors of PFS or OS within our cohort. We conclude that besides immunotherapy, combination therapy with BRAF/MEK inhibitors is a viable option for the treatment of patients with BRAF-mutant melanoma and brain metastases. However, further studies are needed to define the optimal clinical approach in this population.
求助人
不吃早饭的猪猪子 在 2020-09-27 03:55:16 发布,悬赏 10 积分
下载
求助 / 应助时间线
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助lilili采纳,获得10
刚刚
愿爱无忧完成签到,获得积分10
刚刚
瓶里岑发布了新的文献求助10
刚刚
刚刚
无奈发布了新的文献求助30
刚刚
一如果一完成签到,获得积分10
1秒前
1秒前
yehuitao发布了新的文献求助50
1秒前
田様应助钩子89采纳,获得10
1秒前
2秒前
Shicheng完成签到,获得积分10
2秒前
陈媛发布了新的文献求助10
2秒前
飞飞飞发布了新的文献求助10
2秒前
愿爱无忧发布了新的文献求助10
3秒前
啦啦啦完成签到,获得积分10
3秒前
Owen应助三岁半采纳,获得10
3秒前
4秒前
绝不拖延发布了新的文献求助10
4秒前
鹏酱233完成签到,获得积分20
4秒前
4秒前
邱航完成签到,获得积分10
4秒前
4秒前
abb完成签到,获得积分10
4秒前
Ingrid_26发布了新的文献求助30
4秒前
岚婘发布了新的文献求助20
5秒前
6秒前
一如果一发布了新的文献求助10
6秒前
彪壮的美女完成签到,获得积分10
6秒前
追寻的安南完成签到 ,获得积分10
6秒前
Hh发布了新的文献求助20
6秒前
7秒前
九儿发布了新的文献求助10
7秒前
科目三应助瓶里岑采纳,获得10
7秒前
WW完成签到,获得积分10
8秒前
8秒前
8秒前
ppg完成签到,获得积分10
8秒前
端庄的煎蛋完成签到,获得积分0
8秒前
Hello应助Abai采纳,获得10
8秒前
jiangtoali发布了新的文献求助10
8秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Technologies supporting mass customization of apparel: A pilot project 450
China—Art—Modernity: A Critical Introduction to Chinese Visual Expression from the Beginning of the Twentieth Century to the Present Day 430
A Field Guide to the Amphibians and Reptiles of Madagascar - Frank Glaw and Miguel Vences - 3rd Edition 400
China Gadabouts: New Frontiers of Humanitarian Nursing, 1941–51 400
The Healthy Socialist Life in Maoist China, 1949–1980 400
Walking a Tightrope: Memories of Wu Jieping, Personal Physician to China's Leaders 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3790087
求助须知:如何正确求助?哪些是违规求助? 3334781
关于积分的说明 10272224
捐赠科研通 3051278
什么是DOI,文献DOI怎么找? 1674537
邀请新用户注册赠送积分活动 802651
科研通“疑难数据库(出版商)”最低求助积分说明 760828